Open an account

Silexion Therapeutics

SLXN · NASDAQ

$0.1538+$0.0008 (+0.52%)TodayMarket closed ·
Prev close $0.153

About SLXN

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Employees
13
Headquarters
Ramat Gan
Listed
Feb 17, 2021
Sector
Health Care
Industry
Biotechnology
Website
moringaac.com

SLXN key statistics

Market cap
2.23M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
17.74M
Volume
1.12M
Open price
$0.153
High today
$0.1737
Low today
$0.153
52 Week high
$36.50
52 Week low
$0.1416

Silexion Therapeutics (SLXN) at a glance

Silexion Therapeutics (SLXN) last traded at $0.1538, with a market cap of 2.23M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.153 and $0.1737. The current price is 0.5% above the day's low and 11.5% below its high.

Volume so far is 1.12M shares, below the average of 17.74M shares a day.

Over the past year Silexion Therapeutics has ranged from $0.1416 to $36.50, and now sits 0% of the way up that range.

Silexion Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$5.17 per share against an estimate of -$2.16.

The average analyst price target is $5.10, 3216.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $5.10
Low
$5.05
Now
$0.1538
High
$5.25

SLXN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 26.2% on average.

  1. Q3 FY24: reported -$304.51 per share against an estimate of $0.00
  2. Q4 FY24: reported -$3,114.00 per share against an estimate of -$149.94
  3. Q1 FY25: reported -$39.00 per share against an estimate of -$33.66
  4. Q2 FY25: reported -$43.20 per share against an estimate of -$36.72
  5. Q3 FY25: reported -$28.80 per share against an estimate of -$34.68
  6. Q4 FY25: reported -$14.00 per share against an estimate of -$11.42
  7. Q1 FY26: reported -$8.50 per share against an estimate of -$13.16
  8. Q2 FY26: reported -$5.17 per share against an estimate of -$2.16

SLXN news

  • Tanya Rawat

    Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Nasdaq Gains 100 Points; Target Earnings Top Views

Similar companies

Companies in the same industry as Silexion Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.